Skip to main content

Table 4 Cost-effectiveness of different types of pneumococcal conjugate vaccines (PCVs)

From: Economic evaluation of pneumococcal conjugate vaccination in The Gambia

Outcomes

No vaccination

Vaccination

(PCV7)

Vaccination (PCV10)

Vaccination (PCV13)

K = 0 (base-case)

    

Cost (2005 US$)

233,100

906,240

902,040

899,280

Incremental cost (2005 US$)

-

673,140

668,940

666,180

Effectiveness (DALYs)

182,630

181,890

181,630

181,450

Incremental effectiveness (DALYs averted)

-

740

1,000

1,180

ICER (2005 US$/DALY averted)

-

910

670

570

ICER expressed as % per capita GDPa

 

250%

190%

160%

K = 1

    

Cost (2005 US$)

233,100

906,240

902,040

899,280

Incremental cost (2005 US$)

-

673,140

668,940

666,180

Effectiveness (DALYs)

208,670

207,820

207,530

207,330

Incremental effectiveness (DALYs averted)

-

850

1,140

1,340

ICER (2005 US$/DALY averted)

-

800

590

500

ICER expressed as % per capita GDPa

 

220%

160%

140%

  1. DALY: disability-adjusted life year, K = 0: uniform age-weights used in DALY calculation, K = 1: non-uniform age-weights used in DALY calculation, ICER: incremental cost-effectiveness ratio.
  2. a $360 (in 2005 US$) in The Gambia for 2008.